New York, NY -- November 30, 2020 -- InvestorsHub NewsWire -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues a new research report.

Basketball veteran and Reality TV star, Lamar Odom, has accepted a position with TPT Global Tech, Inc. (OTCQB: TPTW) as Vice President of Sports and Entertainment. Lamar will focus on the Company's Global QR code driven End to End Covid-19 testing, monitoring and Check and Verify solutions "QuikLAB," "SaniQuik," and "QuikPass". The Company has developed its global "QuikPass" Check and Verify Monitoring Platform ("Platform") for schools, airlines, hospitals, sports venues, restaurants, hotels and nightclubs.
 Any business on the Platform will be able to "check and verify" the exact date and time said individual has tested for Covid-19 and if that individual is virus free to gain access to any venue. The purpose is to test everyone entering any facility and to verify that they are Covid-19 free. The "QuikPass" Platform also works with third-party testing labs or organizations to participate on the "QuikPass" Network.

According to Optec International, Inc. (OTCPINK: OPTI) CEO, Roger Pawson, "It's absolutely 100% real, it is in progress right now," he continued. "With those kinds of revenues and profits, it only makes sense for us to uplist, not only to the OTCQB and OTCQX, but ultimately to NASDAQ." Pawson made that statement in a discussion about the company’s recent $2 billion order for PPE including face masks, gowns, and hospital-grade gloves, as well as hospital-grade sterilization wipes.
 The company was unable to discuss specifically who placed the order, other than to say it was an international consortium. Optec has recently introduced a line of Touchless Temperature Scanners and UV-C Room Sterilizers. The company is currently marketing their UVC-LED Personal Protection product called OPTEC iWandä as a solution for disinfecting people's immediate surroundings.

See our feature report and stay informed about new biotech developments READ MORE
Copy and paste to browser may be required

Relief Therapeutics Hldg, Inc. (OTCQB: RLFTF) holds a patent issued in the U.S. and multiple other countries covering potential formulations of RLF-100(TM). RLF-100(TM) (Aviptadil) is a formulation of Vasoactive Intestinal Polypeptide (VIP), known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant.
 Since July 2020, more than 150 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100(TM). The FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100(TM) for the treatment of COVID-19 and awarded Fast Track designation. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension. The company is currently conducting a phase 2b/3 clinical trial.

CytoDyn Inc. (OTCQB: CYDY) is developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has reached enrollment of 293 patients in its Phase 3 trial for COVID-19 patients with severe-to-critical symptoms. An interim analysis on the first 195 patients was conducted mid-October and is expected to occur again now that the Company has reached enrollment of 293 patients. leronlimab-PRO 140 is also in clinical trials for HIV-infected patients and metastatic triple-negative breast cancer patients.
 Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases

Our comprehensive feature report here READ MORE
Copy and paste to browser may be required

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering mid, small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is defined on pages, landing pages where a ticker that we have been compensated to mention appears.

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, or “expert” for further information on analyst credentials, please email TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Traders News Source

Relief Therapeutics Hold... (QB) (USOTC:RLFTF)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Relief Therapeutics Hold... (QB) Charts.
Relief Therapeutics Hold... (QB) (USOTC:RLFTF)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Relief Therapeutics Hold... (QB) Charts.